Technology Hardware and Equipment

Switzerland Investor Update Tender

📄 Tender ID: 457465538 📅 Published: 20 Oct 2020

📋 Tender Overview

Lonza provides the details of its new structural design culture and external reporting2023 Group guidance double-digit sales growth CORE EBITDA margin of around 33 - 35 and double-digit ROICCAPEX in 2021 and 2022 is likely to remain at 2019 levelsBiologics and Small Molecules are primary growth drivers with contracted business up high double-digit versus 2019 and new projects in 2020 up 30 versus 2019Updated financial reporting to include divisional KPIs for Sales CORE EBITDA and CAPEX alongside existing Group metricsThe Investor Update was hosted by Albert M. Baehny Chairman and CEO ad interim Lonza Group. He commentedWe have considered areas for review now that Lonza has a dedicated focus on the pharma and biotech industry. Lonzas structural and cultural blueprint will help us to achieve a harmonized one business indentity and provide a greater level of transparency on company performance to our investor and analyst community.The scale of global demand for our products and services is both a measure of resilience and the future growth potential for our business. Our current CAPEX plans for 2021 and 2022 are based on a solid projection of performance which is reflected in the Group guidance. Our future plans are built on the world-class quality of our product and service offering alongside the trust and loyalty we have built within our customer community.Pierre-Alain Ruffieux also attended the presentation in his capacity as future CEO of Lonza Group with his tenure due to commence in November 2020. He commentedThe new business structure culture and financial reporting will provide a critical compass as we navigate our future. It gives me a solid foundation as I commence my new role and work to ensure that Lonza continues to optimize its global potential as a true leader in developing technologies to enable a healthier world.Basel Switzerland 15 October 2020 Today Lonza sets out the new structural blueprint for its LPBN segment. The structure comprises four business divisions1Biologics representing 47 of Group salesCapsules and Health Ingredients representing 27 of Group salesSmall Molecules representing 16 of Group salesCell Gene Therapy and Bioscience representing 10 of Group salesThese will be supported by five strategic global business functions Operations Quality Commercial Marketing Finance and Human Resources. The business is currently in a period of transformation and the new structure will become operational from 1 January 2021. External Financial reporting will be updated to reflect the new structure.The new structure has been developed to increase Divisional end-to-end performance accountability and to strengthen governance and process excellence from Global Functions as Lonza proceeds with the divestment of its LSI segment. The structural design is supported by the set of internal cultural values which include collaboration accountability focus integrity and openness.DIVISIONAL UPDATESThe investor update provides an overview of the operating model for each division. This also included an overview of key statistics and an insight into existing performance and future plans. A summary of 2020 business performance indicators is listed below Contracted business in Biologics and Small Molecules in 2020 is up high double-digit versus 2019 driven by new assets coming on line and strong market demandIn 2020 new customer acquisition across Biologics Small Molecules and Cell Gene Therapy continues showing a 30 increase over 2019New projects in Biologics and Small Molecules in 2020 is up 30 versus 2019New projects in Cell Gene Therapy in 2020 is up 20 versus 2019Additional divisional data can be found in the subsequent section where selected presentation content is included. This includes the followingEstimated growth rates of Business Units CAGR 2020 2023Value chain sales distribution as of total Business Unit sales Biologics FY 2019Growth projections in Mammalian fermentation capacity in kilolitre KLGROUP GUIDANCE 2023Lonza provides the following Group guidance for 2023 double-digit sales growth CORE EBITDA margin of around 33 - 35 and double-digit ROIC.In providing this guidance a series of influencing factors were taken into consideration. The business anticipates double-digit sales growth driven by Biologics Small Molecules and Cell Gene Therapy businesses. More generally double-digit ROIC driven by growth and margin expansion. In this context Lonza Group is confident to deliver an improved CORE EBITDA margin although it is committed to investing in future growth projects. In this context CAPEX in 2021 and 2022 is likely to remain at 2019 levels. Maintaining this balance between performance and investment will allow the business to deliver short-term margin alongside long-term growth. Overview divisional guidance 2023 is available in the section below which includes selected Investor Update presentation content.UPDATED FINANCIAL REPORTINGThe updated financial reporting fully reflects the new divisional structure thereby increasing granularity on Divisional performance for investors. At a divisional level key performance indicators will include sales CORE EBITDA margin and CAPEX. These figures will also be provided for the Group alongside cash flow ROIC CORE EPS and Net Debt CORE EBITDA. The new reporting steering model will also eliminate selected measures including CORE EBIT and CORE RONOA APMs and increase the threshold for non-CORE adjustments to CHF 20m per event.The following additional information is available in the section below which includes selected Investor Update presentation contentImpact of CORE EBITDA adjustments on Group ProfitabilityBridge to new Group reporting structure indicative figures FY 2019Financial performance overview of Divisions H1 2020

🔍 Key Information

📄
Tender Reference No.
457465538
📅
Publication Date
20 Oct 2020
🌐
Sector
Technology Hardware and Equipment
📝
Notice Type
News
📍
Location
Switzerland

📁 Documents & Downloads

No documents found

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
0
days remaining · 20 Oct 2020
🔔 Set Alert

🧭 Quick Facts

Authority N/A
Country Switzerland
State / UT N/A
Tender Type Procurement News
Currency N/A
Similar Tenders
Loading similar tenders…